Skip to main content

Table 3 Efficacy evaluation of sintilimab

From: Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

Efficacy evaluation n %
CR 0 0
PR 17 85.0%
SD 3 15.0%
PD 0 0
ORR (95% CI) 17 85.0% (95% CI: 62.1–96.8%)
DCR (95% CI) 20 100.0% (95% CI: 83.2–100.0%)
  1. CI confidence interval, CR complete response, DCR disease control rate, ORR overall response rate, PD progressive disease, PR partial response, SD stable disease